Equillium, Inc.EQNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank29
3Y CAGR-69.2%
5Y CAGR-66.7%
Studio
Year-over-Year Change

Year-over-year research & development expense growth

3Y CAGR
-69.2%/yr
Annual compound
5Y CAGR
-66.7%/yr
Consistent
Percentile
P29
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
20241.05%
2023-1.35%
202242.34%
202136.09%
20209.89%
2019256.87%
2018270.62%
20170.00%